FDA panel rejects Novartis multiple myeloma drug panobinostat
This article was originally published in Scrip
Executive Summary
The 3.9 months median improvement in progression-free survival (PFS) was not enough to convince the FDA's Oncologic Drugs Advisory Committee (ODAC) on 6 November to recommend Novartis' panobinostat as a treatment for multiple myeloma.